BPC-157 vs ARA-290 (Cibinetide)

BPC-157 and ARA-290 (Cibinetide) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157 is a synthetic 15-amino-acid peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol) derived from a protein found in human gastric juice. It has demonstrated robust regenerative and cytoprotective effects across hundreds of animal studies spanning tendon, ligament, muscle, bone, nerve, GI tract, and blood vessel healing. However, human clinical data is extremely limited — only three pilot studies have examined BPC-157 in humans as of 2025 (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA classifies it as Category 2, prohibiting compounding, and WADA bans its use in sports.

Key claims: Accelerates tendon and ligament healing; Heals gut lining and treats leaky gut; Reverses NSAID-induced GI damage.

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide (MW ~1257 g/mol) derived from the helix B surface of erythropoietin (EPO). Unlike recombinant EPO, ARA-290 does not bind the classical EPO receptor homodimer and therefore does not stimulate erythropoiesis (red blood cell production), avoiding the thrombotic and cardiovascular risks of EPO. Instead, it selectively activates the innate repair receptor (IRR), a heterodimer of EPOR and β-common receptor (CD131), expressed on tissues undergoing stress or damage. ARA-290 received FDA Orphan Drug Designation for treatment of sarcoidosis-associated small fiber neuropathy. Multiple Phase II clinical trials have been completed demonstrating improvements in neuropathic pain, autonomic function, and corneal nerve fiber regeneration.

Key claims: Reduces neuropathic pain in sarcoidosis; Promotes corneal nerve fiber regeneration; Improves metabolic markers in type 2 diabetes.

Both peptides are studied for: Injury Recovery.

BPC-157 is also researched for: Gut Health.

ARA-290 (Cibinetide) is also researched for: no additional unique applications.

BPC-157: No completed randomized controlled human clinical trials for safety assessment Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.

ARA-290 (Cibinetide): Well-tolerated in all completed Phase II trials with no serious drug-related adverse events reported No erythropoietic stimulation — no increase in hemoglobin, hematocrit, or thrombotic risk Most common adverse events: mild injection site reactions, transient headache